Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...

and Novartis' Lucentis (ranibizumab), approved biosimilars of those two drugs, and Roche's Vabysmo (faricimab). Compounded bevacizumab formulations are sometimes used to treat wet AMD but ...

Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant anti-metastatic efficacy in a preclinical study ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC).

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately RMB5.7244 billion, representing ...